✦ LIBER ✦

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer

✍ Scribed by Yong Sang Hong; Jeeyun Lee; Sang Cheol Lee; In Gyu Hwang; Seong-Ho Choi; Jin-Seok Heo; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Won Ki Kang

Publisher: Springer
Year: 2006
Tongue: English
Weight: 391 KB
Volume: 60
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-006-0380-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of epirubicin, cisplatin,

Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma

✍ Se Hoon Park; Yeon Ho Park; Jeong Nam Lee; Soo-Mee Bang; Eun Kyung Cho; Dong Bok 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

A Phase II study of gemcitabine and cisp

A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer

✍ Seung Tai Kim; Joon Oh Park; Jeeyun Lee; Kyu Taek Lee; Jong Kyun Lee; Seong-Ho C 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 3 views

Phase II study with etoposide in previou

Phase II study with etoposide in previously untreated advanced breast cancer

✍ Hans-Erik Wander; Winrich Rauschning; Dirk Meyer; Wolfgang Achterrath; Gerd-Arno 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 281 KB

Phase I study of cediranib in combinatio

Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer

✍ Taroh Satoh; Yasuhide Yamada; Kei Muro; Hidetoshi Hayashi; Yasuhiro Shimada; Dai 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 241 KB

Expanded phase II trial of gemcitabine a

Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer

✍ Rachel P. Riechelmann; Carol A. Townsley; Sheray N. Chin; Gregory R. Pond; Jenni 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

## Abstract ## BACKGROUND. A phase 2 trial of gemcitabine and capecitabine (GemCap) in patients with advanced biliary cancer led to an objective response in approximately 30% of patients and a median survival of 14 months. In the current study, the authors report further efficacy data of a larger

Phase I study of 3-weekly docetaxel, cap

Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer

✍ Sun Jin Sym; Min-Hee Ryu; Hye Jin Kang; Sung Sook Lee; Heung-Moon Chang; Jae Lyu 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 328 KB